StocksMedium•5 November 2026•
1 min read
Gyre Therapeutics Reports $32.9M Q3 Revenue and Affirms 2026 Guidance
Key Facts
1Gyre Therapeutics reported Q3 2026 revenue of $32.9 million.
2The company reported a GAAP basic EPS loss of $0.04.
3The company affirmed its full-year 2026 revenue guidance of $100.5 million to $111.0 million.
Gyre Therapeutics reported revenue of $32.9 million for the third quarter of 2026, according to GlobeNewswire. The company posted a GAAP basic loss per share (EPS) of $0.04. Furthermore, the firm affirmed its full-year 2026 revenue guidance, maintaining a target range of $100.5 million to $111.0 million.
GYRE closed at $4.44 on November 4, 2026, with the stock trading between a session low of $4.33 and a high of $4.65. This financial update marks the first full quarter of operations for the company since the incorporation of Cullgen into its biopharmaceutical business.